Lakefront Biotherapeutics (LKFT) Long-Term Deferred Tax (2013 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Long-Term Deferred Tax for 13 consecutive years, with $190831.5 the latest figure, recorded in Q1 2026.

• In Q1 2026, Long-Term Deferred Tax fell 87.68% year-over-year to $190831.5; the TTM figure through Mar 2026 stood at $190831.5 (down 87.68% YoY), while the FY2025 annual figure was $226988.5, down 85.59% from the prior year.
• Long-Term Deferred Tax fell to $190831.5 in Q1 2026 per LKFT's latest filing, from $226988.5 in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $4.5 million in Q1 2022 and bottomed at $190831.5 in Q1 2026.
• Historically, Long-Term Deferred Tax has averaged $1.4 million across 5 years, with a median of $1.3 million in 2024.
• Annual changes were most pronounced in 2024 — Long-Term Deferred Tax soared 33.09% — and 2026, when it plunged 87.68%.
• Lakefront Biotherapeutics' Long-Term Deferred Tax stood at $1.4 million in 2022, then declined by 14.89% to $1.2 million in 2023, then jumped by 33.09% to $1.6 million in 2024, then slumped by 85.59% to $226988.5 in 2025, then slipped by 15.93% to $190831.5 in 2026.
• Business Quant data shows LKFT's Long-Term Deferred Tax at $190831.5 in Q1 2026, $226988.5 in Q4 2025, and $979668.2 in Q3 2025.